Insiders · KROS

KROS insider transactions

Keros Therapeutics Inc. (KROS) Form 4 insider transactions - real-time wire coverage of every officer, director, and 10% owner trade.

Recent Form 3, 4, and 5 filings for KROS

• 8m
  Director Farzan Nima sold $28,166 worth of shares (2,625 units at $10.73) as part of a pre-agreed trading plan, decreasing direct ownership by 21% to 9,767 units (SEC Form 4)

  4 - Keros Therapeutics, Inc. (0001664710) (Issuer)
• 10m
  Director Knowles Julius sold $28,166 worth of shares (2,625 units at $10.73) as part of a pre-agreed trading plan, decreasing direct ownership by 19% to 10,958 units (SEC Form 4)

  4 - Keros Therapeutics, Inc. (0001664710) (Issuer)
• 2d
  Director Seth Alpna was granted 7,142 shares, increasing direct ownership by 136% to 12,392 units (SEC Form 4)

  4 - Keros Therapeutics, Inc. (0001664710) (Issuer)
• 3d
  Director Seth Alpna sold $28,140 worth of shares (2,625 units at $10.72) as part of a pre-agreed trading plan, decreasing direct ownership by 21% to 9,767 units (SEC Form 4)

  4 - Keros Therapeutics, Inc. (0001664710) (Issuer)
• 3d
  Director Gray Mary Ann was granted 7,142 shares, increasing direct ownership by 136% to 12,392 units (SEC Form 4)

  4 - Keros Therapeutics, Inc. (0001664710) (Issuer)
• 3d
  Director Farzan Nima was granted 7,142 shares, increasing direct ownership by 136% to 12,392 units (SEC Form 4)

  4 - Keros Therapeutics, Inc. (0001664710) (Issuer)
• 3d
  Director Bienaime Jean Jacques was granted 7,142 shares, increasing direct ownership by 76% to 16,592 units (SEC Form 4)

  4 - Keros Therapeutics, Inc. (0001664710) (Issuer)
• 3d
  Director Knowles Julius was granted 7,142 shares, increasing direct ownership by 111% to 13,583 units (SEC Form 4)

  4 - Keros Therapeutics, Inc. (0001664710) (Issuer)
• 20d
  Director Bienaime Jean Jacques bought $10,580 worth of shares (1,000 units at $10.58), increasing direct ownership by 12% to 9,450 units (SEC Form 4)

  4 - Keros Therapeutics, Inc. (0001664710) (Issuer)
• 52d
  SEC Form 4 filed by Bienaime Jean Jacques

  4 - Keros Therapeutics, Inc. (0001664710) (Issuer)
• 63d
  SEC Form 4 filed by Seehra Jasbir

  4 - Keros Therapeutics, Inc. (0001664710) (Issuer)
• 73d
  Amendment: SEC Form 4 filed by Cho Esther

  4/A - Keros Therapeutics, Inc. (0001664710) (Issuer)
• 89d
  SEC Form 4 filed by Keros Therapeutics Inc.

  4 - Keros Therapeutics, Inc. (0001664710) (Issuer)
• 89d
  SEC Form 4 filed by Keros Therapeutics Inc.

  4 - Keros Therapeutics, Inc. (0001664710) (Issuer)
• 89d
  SEC Form 3 filed by Keros Therapeutics Inc.

  3 - Keros Therapeutics, Inc. (0001664710) (Issuer)
• 107d
  Chief Science Officer Lerner Lorena Raquel sold $63,324 worth of shares (3,873 units at $16.35), decreasing direct ownership by 11% to 31,127 units (SEC Form 4)

  4 - Keros Therapeutics, Inc. (0001664710) (Issuer)
• 107d
  CHIEF FINANCIAL OFFICER Regnante Keith sold $77,483 worth of shares (4,739 units at $16.35), decreasing direct ownership by 11% to 39,261 units (SEC Form 4)

  4 - Keros Therapeutics, Inc. (0001664710) (Issuer)
• 107d
  SVP, General Counsel Cho Esther sold $77,581 worth of shares (4,745 units at $16.35), decreasing direct ownership by 11% to 39,755 units (SEC Form 4)

  4 - Keros Therapeutics, Inc. (0001664710) (Issuer)
• 107d
  CHIEF EXECUTIVE OFFICER Seehra Jasbir sold $113,433 worth of shares (7,015 units at $16.17), decreasing direct ownership by 2% to 385,708 units (SEC Form 4)

  4 - Keros Therapeutics, Inc. (0001664710) (Issuer)
• 149d
  SEC Form 4 filed by CHIEF EXECUTIVE OFFICER Seehra Jasbir

  4 - Keros Therapeutics, Inc. (0001664710) (Issuer)
• 171d
  Director Orbimed Advisors Llc returned $3,807,766 worth of shares to the company (214,522 units at $17.75) (SEC Form 4)

  4 - Keros Therapeutics, Inc. (0001664710) (Issuer)
• 171d
  Director Gordon Carl L returned $3,807,766 worth of shares to the company (214,522 units at $17.75) (SEC Form 4)

  4 - Keros Therapeutics, Inc. (0001664710) (Issuer)
• 171d
  Director Knowles Julius returned $5,715,873 worth of shares to the company (322,021 units at $17.75) (SEC Form 4)

  4 - Keros Therapeutics, Inc. (0001664710) (Issuer)
• 233d
  Large owner Pontifax Management 4 G.P. (2015) Ltd. sold $84,975,125 worth of shares (4,787,331 units at $17.75) (SEC Form 4)

  4 - Keros Therapeutics, Inc. (0001664710) (Issuer)
• 236d
  Large owner Adar1 Capital Management, Llc sold $95,659,436 worth of shares (5,389,264 units at $17.75) (SEC Form 4)

  4 - Keros Therapeutics, Inc. (0001664710) (Issuer)
• 276d
  CHIEF EXECUTIVE OFFICER Seehra Jasbir was granted 90,500 shares, increasing direct ownership by 30% to 392,723 units (SEC Form 4)

  4 - Keros Therapeutics, Inc. (0001664710) (Issuer)
• 297d
  New insider Lerner Lorena Raquel claimed ownership of 35,000 shares (SEC Form 3)

  3 - Keros Therapeutics, Inc. (0001664710) (Issuer)
• 297d
  New insider Cho Esther claimed ownership of 44,000 shares (SEC Form 3)

  3 - Keros Therapeutics, Inc. (0001664710) (Issuer)
• 349d
  SEC Form 4 filed by Large owner Adar1 Capital Management, Llc

  4 - Keros Therapeutics, Inc. (0001664710) (Issuer)
• 360d
  SEC Form 4 filed by Large owner Adar1 Capital Management, Llc

  4 - Keros Therapeutics, Inc. (0001664710) (Issuer)
• 362d
  Amendment: SEC Form 4 filed by Director Kariv Tomer

  4/A - Keros Therapeutics, Inc. (0001664710) (Issuer)
• 362d
  Amendment: SEC Form 4 filed by Director Nussbaum Ran

  4/A - Keros Therapeutics, Inc. (0001664710) (Issuer)
• 367d
  Director Farzan Nima was granted 5,250 shares (SEC Form 4)

  4 - Keros Therapeutics, Inc. (0001664710) (Issuer)
• 367d
  Director Knowles Julius was granted 5,250 shares, increasing direct ownership by 441% to 6,441 units (SEC Form 4)

  4 - Keros Therapeutics, Inc. (0001664710) (Issuer)
• 367d
  Director Kariv Tomer was granted 5,250 shares (SEC Form 4)

  4 - Keros Therapeutics, Inc. (0001664710) (Issuer)
• 367d
  Director Gordon Carl L was granted 5,250 shares (SEC Form 4)

  4 - Keros Therapeutics, Inc. (0001664710) (Issuer)
• 367d
  Director Nussbaum Ran was granted 5,250 shares (SEC Form 4)

  4 - Keros Therapeutics, Inc. (0001664710) (Issuer)
• 367d
  Director Seth Alpna was granted 5,250 shares (SEC Form 4)

  4 - Keros Therapeutics, Inc. (0001664710) (Issuer)
• 367d
  Director Gray Mary Ann was granted 5,250 shares (SEC Form 4)

  4 - Keros Therapeutics, Inc. (0001664710) (Issuer)
• 367d
  Director Bienaime Jean Jacques was granted 5,250 shares, increasing direct ownership by 2,625% to 5,450 units (SEC Form 4)

  4 - Keros Therapeutics, Inc. (0001664710) (Issuer)
• 422d
  Large owner Adar1 Capital Management, Llc bought $328,127 worth of shares (34,925 units at $9.40) (SEC Form 4)

  4 - Keros Therapeutics, Inc. (0001664710) (Issuer)
• 422d
  New insider Adar1 Capital Management, Llc claimed ownership of 4,456,706 shares (SEC Form 3)

  3 - Keros Therapeutics, Inc. (0001664710) (Issuer)
• 427d
  CHIEF EXECUTIVE OFFICER Seehra Jasbir exercised 49,367 shares at a strike of $0.30, increasing direct ownership by 20% to 302,223 units (SEC Form 4)

  4 - Keros Therapeutics, Inc. (0001664710) (Issuer)
• 473d
  Chief Operating Officer Rovaldi Christopher was granted 60,000 shares (SEC Form 4)

  4 - Keros Therapeutics, Inc. (0001664710) (Issuer)
• 473d
  Chief Medical Officer Chyung Yung H. was granted 44,000 shares (SEC Form 4)

  4 - Keros Therapeutics, Inc. (0001664710) (Issuer)
• 473d
  CHIEF FINANCIAL OFFICER Regnante Keith was granted 44,000 shares (SEC Form 4)

  4 - Keros Therapeutics, Inc. (0001664710) (Issuer)
• 499d
  Amendment: CHIEF FINANCIAL OFFICER Regnante Keith sold $1,811,600 worth of shares (40,000 units at $45.29) and exercised 40,000 shares at a strike of $16.00 (SEC Form 4)

  4/A - Keros Therapeutics, Inc. (0001664710) (Issuer)
• 572d
  SEC Form 4 filed by Chief Medical Officer Chyung Yung H.

  4 - Keros Therapeutics, Inc. (0001664710) (Issuer)
• 576d
  SEC Form 3 filed by new insider Chyung Yung H.

  3 - Keros Therapeutics, Inc. (0001664710) (Issuer)
• 661d
  Director Gordon Carl L sold $11,002,500 worth of shares (250,000 units at $44.01) (SEC Form 4)

  4 - Keros Therapeutics, Inc. (0001664710) (Issuer)
• 661d
  Director Orbimed Advisors Llc sold $11,002,500 worth of shares (250,000 units at $44.01) (SEC Form 4)

  4 - Keros Therapeutics, Inc. (0001664710) (Issuer)
• 733d
  SEC Form 4 filed by Bienaime Jean Jacques

  4 - Keros Therapeutics, Inc. (0001664710) (Issuer)
• 733d
  New insider Bienaime Jean Jacques claimed ownership of 200 shares (SEC Form 3)

  3 - Keros Therapeutics, Inc. (0001664710) (Issuer)
• 735d
  SEC Form 4 filed by Seth Alpna

  4 - Keros Therapeutics, Inc. (0001664710) (Issuer)
• 735d
  SEC Form 4 filed by Gordon Carl L

  4 - Keros Therapeutics, Inc. (0001664710) (Issuer)
• 735d
  SEC Form 4 filed by Kariv Tomer

  4 - Keros Therapeutics, Inc. (0001664710) (Issuer)
• 735d
  SEC Form 4 filed by Nussbaum Ran

  4 - Keros Therapeutics, Inc. (0001664710) (Issuer)
• 735d
  SEC Form 4 filed by Knowles Julius

  4 - Keros Therapeutics, Inc. (0001664710) (Issuer)
• 735d
  SEC Form 4 filed by Gray Mary Ann

  4 - Keros Therapeutics, Inc. (0001664710) (Issuer)
• 735d
  SEC Form 4 filed by Farzan Nima

  4 - Keros Therapeutics, Inc. (0001664710) (Issuer)